OTC •
Healthcare •
Biotechnology •
Quote as of 08/07/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeOTC
Market Capitalization0.4511 mln
Float43.33 mln
EPS
9.04
Strong
P / E
0.00
Anomalous
Piotroski F-Score
2
/ 9
Weak
Relative Strength
29
/ 100
Underperforming
Debt / Equity
-0.06
Negative equity
Dividend Yield
0.00%
No dividend
Business Description
CERo Therapeutics Holdings Inc. is a California-based biotech company working to develop new cancer treatments using specially modified immune cells. Founded in 2021 and headquartered in South San Francisco, the company is currently focused on its primary drug candidate, CER-1236, which is designed to treat both blood cancers and solid tumors. This treatment uses a patient's own T cells, which are collected, engineered, and returned to the body to fight cancer more effectively.
